NCT06045793View on ClinicalTrials.gov

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

April 21, 2025

Study Completion Date

April 21, 2025

Conditions
Cocaine UseCocaine IntoxicationCocaine ToxicityCocaine AbuseCocaine Adverse Reaction
Interventions
DRUG

TNX-1300 (Injection)

Patients will receive a single IV injection of TNX-1300.

DRUG

Placebo (Injection)

Patients will receive a single IV injection of placebo with usual care (UC).

Trial Locations (6)

37601

University Of Maryland Medical Center, Baltimore

40536

University of Kentucky Chandler Medical Center, Lexington

48202

Henry Ford Health System, Detroit

48235

Wayne State University, Detroit

63110

Washington University, St Louis

77030

Baylor College of Medicine, Ben Taub Hospital, Houston

Sponsors

Collaborators (1)

Premier
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Premier

UNKNOWN

lead

Tonix Pharmaceuticals, Inc.

INDUSTRY